American Diabetes Association

Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
Five advancements in diabetes treatment to watch
Five advancements in diabetes treatment to watchThe healthcare industry continues to focus efforts on treatments that work better, and ideally are less expensive and less invasive for patients.
New therapies show promise in treating diabetes
New therapies show promise in treating diabetesNew updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes.
Statin prescribing varies in patients with diabetesWide variation exists in practice-level statin prescribing for patients with diabetes, according to a new study.
Insurer diabetes program engages consumers, lowers costs
Insurer diabetes program engages consumers, lowers costsAnthem Blue Cross recently launched a year-long diabetes prevention program to educate, treat and support its qualified California members who are at risk of developing type 2 diabetes.
Aggressive blood sugar control slows diabetic eye disease progressionNIH-funded study shows less diabetic retinopathy progression among those who underwent intensive glycemic control.
Humana, ADA partner for patient-centric diabetes education
Humana, ADA partner for patient-centric diabetes educationPatients to assist insurer, association in creating program to ensure its relevancy and practicality for those with diabetes.
Humana partners with ADA to improve patient education
Humana partners with ADA to improve patient educationPatients to assist insurer, association in creating program to ensure its relevancy and practicality for those with diabetes.
GLP-1 receptor more beneficial in reducing blood sugar compared to injectable therapy in Japanese patientsOnce-weekly dulaglutide is an effective treatment option for patients with type 2 diabetes who need to advance to injectable therapy, according to results from a Japanese study presented at the 2015 American Diabetes Association Scientific Sessions in Boston
ADA: Statin therapy for all with diabetes, high CVD riskThe American Diabetes Association (ADA) is calling for all patients with diabetes who are at high risk for cardiovascular disease (CVD) to be treated with statins and lifestyle therapy, according to its recently published guidance in the January issue of Diabetes Care.